5AM Ventures

Dedicated to taking a diversified, hands-on investment approach to creating value in early-stage life science companies

[Nvelop Therapeutics @nvelop_tx]

Today, we celebrate a transformative milestone as the exceptional teams at @chromamedicine and @nvelop_tx unite to form nChroma Bio.

Together, we are embarking on a shared mission to redefine the future of genetic medicines. Stay tuned for what’s next and be sure to follow us @nchromabio.

[Cidara Therapeutics @CidaraThera]

We’re pleased to announce we’ve reached full planned enrollment of 5,000 subjects in our Phase 2b NAVIGATE #ClinicalTrial across sites in the US and UK. Read more about the trial and this important milestone here: https://t.co/t9hXLICooR

[Latest News from Business Wire @NewsFromBW]

Nido Biosciences Announces Publication of Collaborative Research Revealing Clinically Meaningful Endpoints for Spinal and Bulbar Muscular Atrophy https://t.co/ZVDcWoQQy6

[Cidara Therapeutics @CidaraThera]

Today we announced a $105M private placement led by Venrock Healthcare Capital Partners, with significant participation by new and existing life-sciences focused investors. Read more here: https://t.co/0EGIbksdYD

[Rallybio @rallybio]

🚨 Today, Rallybio announced the initiation of the Phase 2 clinical trial investigating RLYB212 in pregnant women at higher risk for HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT).

[Ensoma @EnsomaBio]

We are excited to unveil our 3 lead programs targeting genetic, immune and oncological diseases. These innovative programs leverage our in vivo hematopoietic stem cell engineering platform and aim to address unmet needs in #CGD, #sicklecell disease and solid tumors. We look forward to presenting preclinical data in these programs at the upcoming #SITC24 and #ASH24 meetings. Details: https://t.co/QTyQUuhRd0

[Skye Bioscience @skyebio]

Preliminary data from Skye's newly-developed diet-induced obesity (DIO) model in mice fulfilled its initial objective of showing that peripheral CB1 inhibition achieves significant weight loss without relying on central activity and its risk of neuropsychiatric adverse events. Skye’s peripherally-targeting antibody, nimacimab, a CB1 inverse agonist and antagonist, achieved dose-dependent weight loss of up to 16% compared to vehicle.

Read the full article here: https://t.co/OngOCcbMkm

[F-Prime @FPrimeCapital]

Join host firms @FPrimeCapital, @atlasventure, @5amVentures, @OUP_VC, and RA Capital Management for the 2025 #Science2Startup symposium on Wed, May 14th!

Have a groundbreaking idea for a #biotech #startup?

Submit your application by Fri, Nov 15th: https://t.co/qENO92f8mg

[Rallybio @rallybio]

FNAIT is officially on notice 📢 today, as we're announcing the approval of our lead program, RLYB212, to move into Phase 2 trials in pregnant women at higher risk of alloimmunization and FNAIT (fetal and neonatal alloimmune thrombocytopenia): https://t.co/VmKoEubBps

[CAMP4 Therapeutics @camp4tx]

Yesterday we announced pricing of our Initial Public Offering. Read our full press release here: https://t.co/3LqGBro2XY

[CAMP4 Therapeutics @camp4tx]

We are delighted to enter this collaboration with @BioMarin and leverage the capabilities of our RAP platform to identify druggable regRNA targets. Check out the full release here: https://t.co/kcmshjPVz4

[Enliven Therapeutics @Enliven_Tx]

Today a positive data update from the Phase 1 clincal trial of ELVN-001 was presented at the ESH-iCMLf Annual John Goldman Conference. Learn more about the updated data here: https://t.co/btvzFnlyz2

[Enliven Therapeutics @Enliven_Tx]

ELVN-001 phase 1 trial continues to show anti-CML activity in heavily pre-treated CML patients. We are energized by the progress and the potential to address the need for more efficacious and better tolerated TKIs so people with CML can not only live longer but live better.

[5AM Ventures @5amVentures]

Attention #biotech entrepreneurs and researchers!

Don’t miss your chance to pitch your #startup ideas at #Science2Startup 2025 to top biotech and #pharma executives, VCs, and entrepreneurs in the Boston area.

Applications are due Fri, Nov 15th: https://t.co/uKjs3rCm5K

[Cidara Therapeutics @CidaraThera]

Today we announced two presentations highlighting data on our #influenza drug-Fc conjugate (DFC) candidate at the 2024 OPTIONS XII conference in Brisbane, Australia. Read here for more information on our oral and poster presentations: https://t.co/yRIMaZHtye

[Precede Biosciences @Precede_Bio]

@Precede_Bio is excited to share data at #ESMO24 demonstrating our unique platform’s capability to reveal tumor PSMA expression from a simple blood test that is highly correlated with PSMA-PET imaging.

View press release: https://t.co/3IYO2zB9XZ

#PrecisionMedicine #Healthcare #DrugDevelopment #ProstateCancer

[5AM Ventures @5amVentures]

#Science2Startup 2024 united academics,entrepreneurs, industry leaders & VCs for adynamic exchange of ideas. The symposium showcased exceptional scientists from global research institutions, all working on pioneering advancements in science. Learn more: https://t.co/fMDN5mObK6

[Karius @KariusInc]

We’re thrilled to announce our latest step forward in advancing the field of infectious disease diagnostics: A contract with @BARDA that supports the extension of our capabilities to include RNA pathogen detection.

Read more here:
https://t.co/eIYIAJN1Ea?

#metagenomics #HHS